Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5426]

CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA...

Prof Hope Rugo - University of California, San Francisco, USA

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Advances in PARP inhibitor use for metastatic breast cancer

Prof Hope Rugo - University of California, San Francisco, USA

Advances in PARP inhibitor use for metastatic breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Margetuximab for the treatment of HER2-positive breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced...

Dr Tira Tan - National Cancer Centre, Singapore

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer ( Dr Tira Tan - National Cancer Centre, Singapore )

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in...

Dr Johannes Ettl - Technical University, Munich, Germany

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer ( Dr Johannes Ettl - Technical University, Munich, Germany )

A phase II study of bemcentinib with pembrolizumab in patients with advanced...

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Expanding clinical trial eligibility criteria: Risks and solutions

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Ribociclib plus endocrine therapy improves survival in premenopausal patients...

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

ASCO 2019 and vision for cancer control

Dr Eduardo Cazap - Editor-in-Chief, ecancer

ASCO 2019 and vision for cancer control ( Dr Eduardo Cazap - Editor-in-Chief, ecancer )

More from ecancer